Dostarlimab Drug

Listing Websites About Dostarlimab Drug

Filter Type:


Cancer Drug with 100% Success Rate Achieved

(Right now) They published the findings in The New England Journal of Medicine , confirming a complete clinical response in all 14 people who underwent the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd) locally advanced rectal cancer. Immunotherapy is being used to replace surgery, chemotherapy, and radiation in this novel “immunoablative” therapy. “This innovative clinical trial was led by Andrea Cercek, MD , Section Head of Colorectal Cancer and Co-Director of ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Life extending endometrial cancer drug rolled out on NHS

(1 day(s) ago) Dostarlimab, which is administered through the blood stream at three-week intervals over a 12-week period, is being rolled out through an early access scheme via the Cancer Drugs Fund, and will be offered to 124 women each year " as a second-line treatment for endometrial cancer with high microsatellite instability or mismatch repair deficiency," said NICE. The first drug of its kind for endometrial cancer, it attaches to a specific protein on the surface of cancer cells, helping the patient’s immune system mount a ...

Url:  Visit Now 

Category:  Health Detail Drugs 


IMAGING Management – Ideas and Solutions from Radiology Experts

(8 day(s) ago) Netflix-Style Algorithm for Blueprint of Cancer Racial Disparities in Breast Cancer Cancer Vanishes for Every Patient with Dostarlimab Potential for Racial Bias in AI Algorithms for Radiology Contrast Agent Shortage Sends Ripples through Radiology « One of my passions is getting radiologists working as doctors » « “We should use technology to make data accessible and comprehensible for... » Previous Next Volume 21 - Issue 6, 2021 The Future of Healthcare Architecture and the Battle Against COVID-19 and ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Health Care Provider Resource Center

(9 day(s) ago) Approved checkpoint inhibitors include: anti-CTLA-4 therapy ipilimumab anti-PD-1 therapies pembrolizumab, nivolumab, cemiplimab and dostarlimab anti-PD-L1 therapies atezolizumab, avelumab and durvalumab anti-LAG-3 therapy relatlimab Adoptive cellular therapies are another form of immunotherapy. The only Food and Drug Administration (FDA)-approved options are CAR T cell therapies, which are created from T cells taken from the patient. The cells are engineered to better recognize the cancer, expanded to ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Immunotherapy for Uterine Cancer

(9 day(s) ago) Dostarlimab (Jemperli): a checkpoint inhibitor that targets the PD-1 pathway; approved for subsets of patients with recurrent or advanced endometrial cancer with mismatch repair deficiency (dMMR) Pembrolizumab (Keytruda®): a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with advanced endometrial cancer, including those with tumors with high microsatellite instability (MSI-H) or high tumor mutational burden (TMB-H); also approved in combination with lenvatinib ...

Url:  Visit Now 

Category:  Health Detail Drugs 


GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers - MedCity News

(10 day(s) ago) Scientists at Memorial Sloan Kettering Cancer Center wanted to see whether using the approved GSK checkpoint blocking-drug dostarlimab (marketed as Jemperli) could replace some or all of the chemo, radiation, and surgery regimen that is the standard of care for rectal cancer. The clinical trial started by swapping out chemo for Jemperli. So far, it’s the only treatment patients have needed. The Phase 2 study has enrolled 18 patients to date.

Url:  Visit Now 

Category:  Health Detail Drugs 


Business News, Finance News, India News, BSE/NSE News, Stock Markets News, Sensex NIFTY, Budget 2022

(10 day(s) ago) Private players seek govt intervention as fuel shortage rises in India Military says Agnipath scheme here to stay; recruitment begins in August Domestic toy makers see surge in sales after dip in Chinese imports » More Will be happy if fare caps are increased: Vistara CEO Vinod Kannan The civil aviation ministry had imposed lower and upper limits on domestic airfares based on flight duration on May 25, 2020 Sequoia India asks court to dismiss lawsuit by its former counsel AI reorganising itself under Tatas; won't comment ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Clinical Trial: Dostarlimab, anti–PD-1 monoclonal antibody in Neuroendocrine Carcinoma

(12 day(s) ago) I set about researching the trials database and came up with one mention of Dostarlimab in a combo treatment for Small Cell Lung Cancer (technically a Neuroendocrine Carcinoma) and other “high grade” Neuroendocrine Carcinomas. In fact, the clinical trial divides these two groupings into cohorts. The reason this one caught my eye was that there is no mention of dMMR/MSI positivity criteria which means a wider scope but only doctors would be able to confirm that assumption. Read more about this trial here ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Issue 23 - The Cancer Letter

(12 day(s) ago) Clinical In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care FreeObituary Moffitt’s Robert Gillies, “father of radiomics,” dies at 69 FreeObituary Lucius Sinks, a giant in pediatric cancer, dies at 91 • “We were able to come together at Roswell Park and help the kids.” FreeObituary Lucius Sinks was the type ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Jemperli Receives Accelerated Approval to Treat Solid Tumors - Benecard

(12 day(s) ago) FDA has approved a new indication for Jemperli® (dostarlimab-gxly), manufactured by GlaxoSmithKline. The drug is now indicated to treat adults who have mismatch repair- deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. Because Jemperli received accelerated approval for this use, continued approval of the indication may be contingent upon verification ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Every Patient Enrolled in Experimental Study Saw Their Cancer Disappear - Scrubs | The Leading Lifestyle Magazine for the Healthcare Community

(14 day(s) ago) They received six months of treatment involving an immunotherapy drug called dostarlimab, manufactured by the company GlaxoSmithKline, which helped fund the study, published Sunday in the New England Journal of Medicine . By the end of the trial, the cancer was undetectable by physical exam, endoscopy, or PET and MRI scans, researchers said. One patient, Sascha Roth, was on her way to New York for weeks of radiation treatment when she heard the good news that she no longer had rectal cancer. “I told my ...

Url:  Visit Now 

Category:  Health Detail Drugs 


GSK's Daprodustat Comes Out Strong for CKD-Related Anemia, But What About its Heart Safety Profile?

(14 day(s) ago) Related: GSK’s Dostarlimab Wins FDA Approval for dMMR Endometrial Cancer Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). It was developed based on Nobel Prize-winning findings of how cells sense and adapt to oxygen availability. In the ASCEND trials, Daprodustat was comparable to Amgen’s Aranesp (darbepoetin alfa), an erythropoiesis-stimulating agent (ESA), with respect to heart safety. Darbepoetin alfa is a synthetic version of the hormone ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Immuno and precision oncology

(14 day(s) ago) The latest addition to the list of tumor agnostic approval is dostarlimab-gxly for adults with MSI high tumors based on the results of GARNET trial. For patients with localized esophageal or esophagogastric junction cancer who have residual disease in the surgical specimen after initial chemoradiotherapy, adjuvant nivolumab for 1 year has been approved recently. Similarly, for renal cell carcinoma, KEYNOTE-564 showed 1 year of adjuvant pembrolizumab improved disease-free survival (DFS) compared with ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Colorectal Cancer

(14 day(s) ago) Colorectal cancer is a malignant neoplasm of the colon or rectum, most commonly adenocarcinoma; clinical presentation ranges from asymptomatic to imminently life threatening (eg, perforation, obstruction) Often detected by screening or by evaluation of anemia, weight loss, or blood in stool Diagnosis is based on history and physical examination findings, confirmed with colonoscopy, and made conclusive with pathology review of specimen After tissue diagnosis, additional laboratory tests and imaging are required to assess ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Unexpected Breakthrough in Experimental Cancer Drug As Researchers Say All Patients in Remission - Pain Resource

(15 day(s) ago) The drug, called dostarlimab, was used in a small trial at New York’s Memorial Sloan Kettering Cancer Center (MSK) for six months. Results from the trial show that every single patient involved saw their tumors disappear. The trial consisted of 18 people, with researchers involved with the study saying “there is still more to be learned” about exactly how this experimental cancer drug works. “We’d certainly never seen this before, it’s really what cancer doctors’ dreams are made of said Dr.

Url:  Visit Now 

Category:  Health Detail Drugs 


Home - Health Analytics Asia

(15 day(s) ago) N Ahmad Earlier this week, a drug called Dostarlimab wiped out rectal cancer in a small group of patients who took it for about […]

Url:  Visit Now 

Category:  Health Detail Drugs 


JEMPERLI (Dostarlimab-gxly) Injection: Endometrial Cancer Treatment

(15 day(s) ago) Jemperli is a PD-1–blocking antibody used for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following previous treatment with a platinum-containing regimen and solid tumours, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. Recommended Dosage: The proposed dosage of Jemperli is: Dose 1’st through Dose 4’th: 500 mg ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Breakthrough Findings for Rectal Cancer Patients | Fight Colorectal Cancer

(15 day(s) ago) This exploratory clinical trial treated 14 patients with stage II and III MMRd (mismatch repair deficient) rectal cancer for six months with the anti PD-1 monoclonal antibody dostarlimab-gxly. MMRd is an inherited or acquired defect in the mechanism that repairs defects in DNA that can occur as cells divide. Because these defects are not repaired in patients with MMRd cancer, cells in patients with this type of tumor become better targets enhancing the effectiveness of immuno-oncology drugs that target ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Management Team :: Actinium Pharmaceuticals, Inc. (ATNM)

(15 day(s) ago) At GSK, he established the U.S. medical affairs oncology team that oversaw the launch readiness plans for three novel oncology products—Blenrep® in multiple myeloma, Zejula® in ovarian cancer, and dostarlimab in endometrial cancer. In addition to GSK, Dr. Desai has overseen the clinical development, implementation and delivery of oncology life cycle management plans for various oncology therapies at several leading global pharmaceutical companies, including Eli Lilly & Company (Lilly), Janssen ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Antibody Therapy Alone Eliminates Certain Rectal Cancers

(15 day(s) ago) The participants received dostarlimab, a PD-1 blocking monoclonal antibody agent, intravenously every three weeks for six months. The researchers hoped that the drug would improve the participants’ chances, but they certainly were not ready for what was to come: after receiving the antibody treatment, all patients demonstrated so-called “clinical complete response”, which means that there was no evidence of tumor as measured by MRI, PET, endoscopic evaluation, digital rectal examination, or biopsy. ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Dostarlimab - Wikipedia

(16 day(s) ago) Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as a medication for the treatment of endometrial cancer. The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation. Additional common side effects reported in the EU include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low levels of thyroid hormones). Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.

Url:  Visit Now 

Category:  Health Detail Drugs 


Dostarlimab Uses, Side Effects & Warnings - Drugs.com

(16 day(s) ago) Generic name: dostarlimab [ dos-TAR-li-mab ] • Brand name: Jemperli • Dosage form: intravenous solution (500 mg/10 mL) • Drug class: Anti-PD-1 monoclonal antibodies Medically reviewed by Drugs.com on May 26, 2021. Written by Cerner Multum. Dostarlimab is used to treat a certain type of uterine cancer after other treatments did not work or stopped working. Your doctor will make sure you have the correct tumor type to be treated with dostarlimab.

Url:  Visit Now 

Category:  Health Detail Drugs 


Dostarlimab-gxly Injection: MedlinePlus Drug Information

(16 day(s) ago) Dostarlimab-gxly injection comes as a solution (liquid) to inject intravenously (into a vein) over 30 minutes by a doctor or nurse in a medical facility or infusion center. It is usually given once every 3 weeks for 4 cycles, and then once every 6 weeks for as long as your doctor recommends you receive treatment. Dostarlimab-gxly injection may cause serious or life-threatening reactions during an infusion. A doctor or nurse will watch you closely while you are receiving the infusion to be sure you are ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Dostarlimab-Gxly (Intravenous Route) Description and Brand Names - Mayo Clinic

(16 day(s) ago) Descriptions Dostarlimab-gxly injection is used to treat endometrial cancer (cancer of the lining of the uterus or womb) that is mismatch repair deficient (dMMR) in patients whose cancer has returned, or it has spread or cannot be removed by surgery. It is given to patients who have received other cancer medicines (eg, platinum) that did not work well. Your doctor will perform a test to check for the dMMR tumor before you use this medicine. Dostarlimab-gxly is a monoclonal antibody that changes the ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Dostarlimab (Jemperli) Cures Colorectal Cancer without the Need for Surgery or Chemotherapy - Gilmore Health News

(16 day(s) ago) A small clinical trial conducted at Memorial Sloane Kettering Cancer Center in New York showed impressive results: 100% of the patients in the trial went into remission without the need for surgery or chemotherapy after treatment with the therapeutic antibody Dostarlimab. In a small group of 12 patients with stage II or III rectal adenocarcinoma, Dostarlimab achieved tumor eradication after one injection every three weeks for six months. In 100% of patients, the tumor was undetectable on CT, MRI, endoscopy, and rectal ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Neoadjuvant dostarlimab is a promising treatment option in locally advanced dMMR rectal cancer | 2 Minute Medicine

(16 day(s) ago) All neoadjuvant dostarlimab patients had a clinical complete response and no patients needed any additional treatments at the study data cutoff. 2. There were no adverse events of grades 3 or higher. Most common adverse events of any grade were dermatitis, pruritus, fatigue, and nausea. Study Rundown: Immune checkpoint inhibitors have had great success as a first-line treatment for patients with mismatch repair-deficient (dMMR) metastatic colorectal cancer.

Url:  Visit Now 

Category:  Health Detail Drugs 


Dostarlimab-Gxly Intravenous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD

(16 day(s) ago) Dostarlimab may cause hormone gland problems (such as thyroid, pituitary, adrenal, pancreas). Your body could make too much or too little hormone. Tell your doctor right away if you have any symptoms such as: cold or heat intolerance, unexplained weight loss/gain, increased thirst/urination, mood or behavior changes (such as decreased sex drive, irritability, forgetfulness), slow/fast/pounding/irregular heartbeat, unusual tiredness, constipation. Get medical help right away if you have any very serious ...

Url:  Visit Now 

Category:  Health Detail Drugs 


JEMPERLI 500 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)

(16 day(s) ago) The recommended dose as monotherapy is 500 mg dostarlimab every 3 weeks for 4 cycles followed by 1000 mg every 6 weeks for all cycles thereafter. Table 1. Dosage regimen for patients treated with JEMPERLI Administration of dostarlimab should continue according to the recommended schedule until disease progression or unacceptable toxicity (see section 5.1). Dose reduction is not recommended.

Url:  Visit Now 

Category:  Health Detail Drugs 


Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design | Future Oncology

(16 day(s) ago) Here, we present the rationale and study design of the innovative DREAMM-5 platform trial, evaluating combinations of belamaf with other anticancer agents, including novel agents GSK3174998 (an OX40 agonist mAb), feladilimab (an ICOS agonist mAb, GSK3359609), nirogacestat (a small molecule gamma-secretase inhibitor, PF-03084014) and dostarlimab (an anti-PD-1 mAb, GSK4057190). The aim of the study is to identify safe and effective belamaf combinations for the treatment of RRMM. Study design & treatment ...

Url:  Visit Now 

Category:  Health Detail Drugs 


Prior authorization drugs

(16 day(s) ago) JEMPERLI (dostarlimab) – (PDF, 1.1 MB) Opens in a new window. JINARC (tolvaptan) – (PDF, 1.1 MB) Opens in a new window. JUXTAPID (lomitapide) – (PDF, 1.1 MB) Opens in a new window. KALYDECO (ivacaftor) – (PDF, 1.1 MB) Opens in a new window.

Url:  Visit Now 

Category:  Health Detail Drugs